Neutrophils as effector cells for antibody-based immunotherapy of cancer

被引:99
作者
van Egmond, Marjolein [1 ,2 ]
Bakema, Jantine E. [2 ]
机构
[1] Vrije Univ Amsterdam Med Ctr, Dept Surg, NL-1081 BT Amsterdam, Netherlands
[2] Vrije Univ Amsterdam Med Ctr, Dept Mol Cell Biol & Immunol, NL-1081 BT Amsterdam, Netherlands
关键词
Monoclonal antibody; Neutrophil; Fc receptor; Immunoglobulin A; Tumour cell; FC-ALPHA-RI; COLONY-STIMULATING FACTOR; GROWTH-FACTOR RECEPTOR; HUMAN POLYMORPHONUCLEAR NEUTROPHILS; ANTI-CD20; MONOCLONAL-ANTIBODIES; CHRONIC LYMPHOCYTIC-LEUKEMIA; METASTATIC BREAST-CANCER; NON-HODGKINS-LYMPHOMA; GAMMA-RI; BISPECIFIC ANTIBODY;
D O I
10.1016/j.semcancer.2012.12.002
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The use of monoclonal antibodies (mAbs) has become a mainstream strategy for the treatment of cancer. After binding to the target antigen, they mediate a plethora of effector functions for elimination of tumour cells. These range from direct effects like induction of apoptosis or growth inhibition of tumour cells to activation of immune system components, including the initiation of complement-dependent lysis or recruitment of immune effector cells. Neutrophils are generally not considered as potential effector cells. However, the most abundant population of circulating white blood cells consists of neutrophils, which express Fc receptors for both immunoglobulin (Ig) G and IgA. In the presence of mAbs that are directed against tumour cells, they execute potent cytotoxic functions. Moreover, as they play a role in regulating adaptive immunity, neutrophil activation may lead to the generation of anti-tumour immune responses as well. This article addresses the possibility of exploiting neutrophils for mAb-based immunotherapy of cancer. (C) 2013 Elsevier Ltd. All rights reserved.
引用
收藏
页码:190 / 199
页数:10
相关论文
共 125 条
[1]   Neutrophils express CD52 and exhibit complement-mediated lysis in the presence of alemtuzumab [J].
Ambrose, Lyn R. ;
Morel, Anne-Sophie ;
Warrens, Anthony N. .
BLOOD, 2009, 114 (14) :3052-3055
[2]   Understanding rituximab function and resistance: implications for tailored therapy [J].
Amoroso, Alfredo ;
Hafsi, Sameh ;
Militello, Loredana ;
Russo, Alessia E. ;
Soua, Zohra ;
Mazzarino, Maria C. ;
Stivala, Franca ;
Libra, Massimo .
FRONTIERS IN BIOSCIENCE-LANDMARK, 2011, 16 :770-782
[3]   Neutrophil Function: From Mechanisms to Disease [J].
Amulic, Borko ;
Cazalet, Christel ;
Hayes, Garret L. ;
Metzler, Kathleen D. ;
Zychlinsky, Arturo .
ANNUAL REVIEW OF IMMUNOLOGY, VOL 30, 2012, 30 :459-489
[4]   The human immunoglobulin A Fc receptor FcαRI: a multifaceted regulator of mucosal immunity [J].
Bakema, J. E. ;
van Egmond, M. .
MUCOSAL IMMUNOLOGY, 2011, 4 (06) :612-624
[5]   Signaling through mutants of the IgA receptor CD89 and consequences for Fc receptor γ-chain interaction [J].
Bakema, Jantine E. ;
de Haij, Simone ;
den Hartog-Jager, Constance F. ;
Bakker, Johanna ;
Vidarsson, Gestur ;
van Egmond, Marjolein ;
de Winkel, Jan G. J. van ;
Leusen, Jeanette H. W. .
JOURNAL OF IMMUNOLOGY, 2006, 176 (06) :3603-3610
[6]   Immunoglobulin A A next generation of therapeutic antibodies? [J].
Bakema, Jantine E. ;
van Egmond, Marjolein .
MABS, 2011, 3 (04) :352-361
[7]   Targeting FcαRI on Polymorphonuclear Cells Induces Tumor Cell Killing through Autophagy [J].
Bakema, Jantine E. ;
Ganzevles, Sonja H. ;
Fluitsma, Donna M. ;
Schilham, Marco W. ;
Beelen, Robert H. J. ;
Valerius, Thomas ;
Lohse, Stefan ;
Glennie, Martin J. ;
Medema, Jan Paul ;
van Egmond, Marjolein .
JOURNAL OF IMMUNOLOGY, 2011, 187 (02) :726-732
[8]   Cross-talk in the innate immune system: Neutrophils instruct recruitment and activation of dendritic cells during microbial infection [J].
Bennouna, S ;
Bliss, SK ;
Curiel, TJ ;
Denkers, EY .
JOURNAL OF IMMUNOLOGY, 2003, 171 (11) :6052-6058
[9]   Oncogenic activation of the RAS/RAF signaling pathway impairs the response of metastatic colorectal cancers to anti-epidermal growth factor receptor antibody therapies [J].
Benvenuti, Silvia ;
Sartore-Bianchi, Andrea ;
Di Nicolantonio, Federica ;
Zanon, Carlo ;
Moroni, Mauro ;
Veronese, Silvio ;
Siena, Salvatore ;
Bardelli, Alberto .
CANCER RESEARCH, 2007, 67 (06) :2643-2648
[10]   The high-affinity IgG receptor, FcγRI, plays a central role in antibody therapy of experimental melanoma [J].
Bevaart, L ;
Jansen, MJH ;
van Vugt, MJ ;
Verbeek, JS ;
van de Winkel, JGJ ;
Leusen, JHW .
CANCER RESEARCH, 2006, 66 (03) :1261-1264